A Comparison of Conventional and Accelerated Corneal Crosslinking: Corneal Epithelial Remodeling and In Vivo Confocal Microscopy Analysis

Abstract

Abstract Purpose To evaluate the effect of conventional and accelerated corneal crosslinking (CXL) on visual acuity, corneal topography, corneal epithelial thickness, and subbasal nerve morphology in progressive keratoconus patients. Methods In this prospective and randomized study, twenty eyes of 20 patients were treated with conventional CXL (3mW/cm2, 30 minutes, C-CXL) and 19 eyes of 19 patients were treated with accelerated CXL (9 mW/cm2, 10 minutes, A-CXL). The spherical equivalent (SE), uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), keratometric measurements, demarcation line measurement and epithelial thickness mapping analyses, and subbasal nerve morphology with in vivo confocal microscopy (IVCCM) were evaluated at baseline and at postoperative months 1, 3 and 6. Results At postoperative 6 months, a significant improvement was observed in all keratometric values in both treatment groups (p < 0.05). All epithelial thickness indices, except central, temporal, and inferotemporal thickness, were reduced at 1 month postoperatively in both treatment groups. The epithelial map uniformity indices (standard deviation and difference between min-max thickness) were significantly lower than the baseline values at all time points after CXL in both treatment groups (p < 0.001). Compared with the preoperative values, there was a significant decrease in all IVCCM parameters at 1 month postoperatively (p < 0.05). At 6 months postoperatively, corneal nerve fiber density and corneal nerve branch density recovered to preoperative values in the A-CXL group, whereas corneal nerve regeneration was not complete in the C-CXL group. Conclusion Both conventional and accelerated CXL treatments appear to be effective in halting the progression of KC. Corneal epithelial irregularity slightly improves after CXL. The regeneration of subbasal nerves is faster after A- CXL treatment.